文献速递乳房整形与再造创面修复

组织扩张器乳房再造术后血肿的临床结局:627例分析

Clinical Outcomes After Hematoma Development: A Study of 627 Tissue Expander Breast Reconstructions.
PubMed 文献 · Ann Plast Surg · 2020-01-01

单机构回顾性分析2001至2018年627例组织扩张器即刻乳房再造,术后血肿发生率为4.1%。血肿组假体丢失率15.4%、再造失败率11.5%,均显著高于无血肿组;血肿手术清除者后续并发症和再手术率低于保守处理者。

要点

  • 血肿组假体丢失率15.4%、再造失败率11.5%,显著高于无血肿组的3.7%和2.8%。
  • 血肿手术清除者后续并发症22.2%、再手术5.6%,低于保守处理者的62.5%和27.5%。
  • 口服抗血栓药患者输血率50%,显著高于未用药者的0%。

核心结论

  • 组织扩张器即刻乳房再造术后血肿可能危及再造成功,应密切监测。
  • 口服抗血栓药患者可能更易发生大体积血肿和再造失败。
  • 建议积极手术清除术后血肿以减少后续并发症和再手术。

研究设计与样本

  • 单机构回顾性研究,分析2001至2018年627例组织扩张器即刻乳房再造。

主要发现

  • 术后血肿发生于4.1%(n=26)的再造,无血肿者占95.9%(n=601)。
  • 血肿组假体丢失率15.4% vs 3.7%(P=0.0033),再造失败率11.5% vs 2.8%(P=0.0133)。
  • 血肿手术清除组后续并发症22.2% vs 62.5%(P=0.046),再手术5.6% vs 27.5%(P=0.037)。
  • 口服抗血栓药组输血率50% vs 0%(P=0.001),血肿体积330 vs 169.3 mL(P=0.078),再造失败33.3% vs 5%(P=0.057)。

临床怎么用

  • 对组织扩张器乳房再造术后血肿应密切监测并积极手术清除。
  • 对口服抗血栓药患者应警惕大体积血肿和再造失败风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hematomas after tissue expander immediate breast reconstruction (TE-IBR) pose a significant challenge during the recovery period. In this study, we aim to evaluate whether hematoma formation leads to subsequent complications and how management can impact final reconstructive goals. METHODS: A single-institution retrospective review of TE-IBRs from 2001 to 2018 was performed using an established breast reconstruction database. Demographics, medications, comorbidities, and complications were identified. Implant loss was defined as removal of the tissue expander/implant without immediate reimplantation during that operation. Hematoma size, management, transfusion requirement, reoperations, and final outcome were recorded. Reconstructive failure was defined as an implant loss that was not replaced with another implant or required secondary autologous reconstruction. RESULTS: Six hundred twenty-seven TE-IBR patients were analyzed. Postoperative hematoma (group 1) occurred in 4.1% (n = 26) of TE-IBRs and did not develop in 95.9% (group 2: n = 601). Group 2 had a higher mean body mass index (24.5 vs 27.3 kg/m, P = 0.018); however, there were no significant differences in smoking status, preoperative/postoperative radiation/chemotherapy, or other comorbidities. Group 1 was found to have increased rates of implant loss (15.4% vs 3.7%, P = 0.0033) and reconstructive failure (11.5% vs 2.8%, P = 0.0133) compared with group 2.Eighteen hematomas (69.2%) underwent surgical intervention (group 1a) compared with 30.8% (n = 8) that were clinically managed (group 1b). Group 1a had statistically significant lower rates of subsequent complications (22.2% vs 62.5%, P = 0.046) and reoperations (5.6% vs 27.5%, P = 0.037) than did group 1b, respectively.Lastly, 23.1% (n = 6) of patients who developed a hematoma were on home antithrombotics (group 1c) compared with 76.9% (n = 20) of patients with no antithrombotics (group 1d). There were statistically significant differences in transfusion rates (50% vs 0%, P = 0.001) between groups 1c and 1d, respectively. Differences in hematoma volume (330 vs 169.3 mL, P = 0.078) and reconstructive failure (33.3% vs 5%, P = 0.057) approached significance between both groups. CONCLUSIONS: Hematoma after TE-IBR should be monitored closely, as it may play a role in jeopardizing reconstruction success. Patients on home antithrombotic medication may be at increased risk of larger-volume hematomas and reconstruction failure. Plastic surgeons should consider aggressive surgical evacuation of postoperative TE-IBR hematomas to reduce subsequent complications and reoperations, thus optimizing reconstructive outcomes.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Rogoff H, Marquez JE, Ghosh K, et al. Clinical Outcomes After Hematoma Development: A Study of 627 Tissue Expander Breast Reconstructions. Ann Plast Surg. 2020. PMID: 32243320. doi:10.1097/SAP.0000000000002343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。